From: Pharmaceutical efficacy of harmalol in inhibiting hepatocellular carcinoma
Group no. | Treatment | No. of Mice | Final weight (g) | 1st week | 7th week | 14th week | 21st week |
---|---|---|---|---|---|---|---|
I | Control (untreated) | 5 | Body | 25.3 ± 2.1 | 25.7 ± 2.3 | 26.1 ± 2.2 | 26.3 ± 2.1 |
Liver | 1.69 ± 0.13 | 1.68 ± 0.12 | 1.69 ± 0.14 | 1.69 ± 0.13 | |||
II | Harmalol treated | 5 | Body | 25.6 ± 2.3 | 26.2 ± 2.1 | 26.8 ± 2.4 | 25.1 ± 2.3 |
Liver | 1.66 ± 0.11 | 1.57 ± 0.12 | 1.58 ± 0.14 | 1.55 ± 0.13 | |||
III | CCl4 treated | 5 | Body | 25.2 ± 3.1 | 22.6 ± 3.1 | 19.1 ± 3.4 | 17.3 ± 3.2* |
Liver | 1.62 ± 0.28 | 1.56 ± 0.22 | 1.43 ± 0.32 | 1.35 ± 0.36* | |||
IV | DEN treated | 5 | Body | 24.5 ± 1.9 | 20.2 ± 1.5 | 17.5 ± 1.1 | 15.6 ± 1.2* |
Liver | 1.50 ± 0.27 | 1.41 ± 0.25 | 1.33 ± 0.14* | 1.19 ± 0.11* | |||
V | DEN+CCl4 treated | 5 | Body | 20.2 ± 2.9 | 18.3 ± 3.6 | 15.4 ± 2.7 | 13.6 ± 1.6* |
Liver | 1.45 ± 0.16 | 1.32 ± 0.19 | 1.23 ± 0.33* | 0.96 ± 0.9* | |||
VI | Pre-treatment with harmalol | 5 | Body | 25.5 ± 2.5 | 25.3 ± 2.8 | 24.6 ± 2.8 | 24.1 ± 2.3* |
Liver | 1.59 ± 0.17 | 1.57 ± 0.22 | 1.56 ± 0.27 | 1.49 ± 0.23* | |||
VII | Post-treatment with harmalol | 5 | Body | 20.6 ± 2.4 | 18.2 ± 2.6* | 22.8 ± 2.2* | 24.9 ± 1.8 |
Liver | 1.47 ± 0.24 | 1.33 ± 0.29* | 1.46 ± 0.25* | 1.66 ± 0.23 |